Tekla Capital Management’s Foamix Pharmaceuticals Ltd. Ordinary Shares FOMX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-300,781
| Closed | -$1M | – | 224 |
|
|
2019
Q4 | $1M | Hold |
300,781
| – | – | 0.04% | 180 |
|
|
2019
Q3 | $914K | Hold |
300,781
| – | – | 0.04% | 162 |
|
|
2019
Q2 | $716K | Hold |
300,781
| – | – | 0.03% | 173 |
|
|
2019
Q1 | $1.13M | Sell |
300,781
-300,424
| -50% | -$1.13M | 0.05% | 157 |
|
|
2018
Q4 | $2.16M | Sell |
601,205
-126,000
| -17% | -$548K | 0.09% | 125 |
|
|
2018
Q3 | $4.17M | Sell |
727,205
-203,193
| -22% | -$1.16M | 0.15% | 105 |
|
|
2018
Q2 | $4.66M | Hold |
930,398
| – | – | 0.18% | 96 |
|
|
2018
Q1 | $4.77M | Hold |
930,398
| – | – | 0.19% | 92 |
|
|
2017
Q4 | $5.59M | Hold |
930,398
| – | – | 0.22% | 83 |
|
|
2017
Q3 | $5.16M | Hold |
930,398
| – | – | 0.18% | 88 |
|
|
2017
Q2 | $4.32M | Hold |
930,398
| – | – | 0.16% | 92 |
|
|
2017
Q1 | $4.61M | Hold |
930,398
| – | – | 0.18% | 88 |
|
|
2016
Q4 | $10.3M | Sell |
930,398
-35,667
| -4% | -$336K | 0.44% | 55 |
|
|
2016
Q3 | $8.95M | Hold |
966,065
| – | – | 0.34% | 67 |
|
|
2016
Q2 | $6.13M | Hold |
966,065
| – | – | 0.25% | 81 |
|
|
2016
Q1 | $6.3M | Buy |
966,065
+313,920
| +48% | +$2.02M | 0.27% | 74 |
|
|
2015
Q4 | $5.29M | Buy |
652,145
+38,568
| +6% | +$288K | 0.19% | 93 |
|
|
2015
Q3 | $4.5M | Buy |
613,577
+199,777
| +48% | +$2.04M | 0.16% | 105 |
|
|
2015
Q2 | $4.24M | Buy |
+413,800
| New | +$4.57M | 0.15% | 89 |
|
Tekla Capital Management's FOMX Position: Q1 2020 in Review
Tekla Capital Management sold out of Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) in Q1 2020, closing a stake of 300,781 shares — an estimated $1M sold.
Tekla Capital Management first reported a position in FOMX in Q2 2015 and held it in 19 quarters. The position peaked at $10.3M in Q4 2016. 3 funds tracked by Wall St. Rank hold FOMX as of Q1 2020.
- Tekla Capital Management reported no remaining Foamix Pharmaceuticals Ltd. Ordinary Shares position as of Q1 2020 after selling out during the quarter.
- Tekla Capital Management sold 300,781 Foamix Pharmaceuticals Ltd. Ordinary Shares shares in Q1 2020, an estimated $1M.
- Tekla Capital Management first reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares in Q2 2015 and held it in 19 quarters.
- Tekla Capital Management's Foamix Pharmaceuticals Ltd. Ordinary Shares position peaked at $10.3M in Q4 2016.
- 3 funds tracked by Wall St. Rank held Foamix Pharmaceuticals Ltd. Ordinary Shares as of Q1 2020.
Based on Tekla Capital Management's 13F filing for Q1 2020, filed 14 May 2020.